Acute interstitial nephritis and PR3-ANCA following reintroduction of pembrolizumab: a case report.

abstract：:Meningiomas are increasingly appreciated to share similar features with other intra-axial central nervous system neoplasms as well as systemic cancers. Immune checkpoint inhibition has emerged as a promising therapy in a number of cancers, with durable responses of years in a subset of patients. Several lines of evide...

journal_title：Immunotherapy

authors： Bi WL,Wu WW,Santagata S,Reardon DA,Dunn IF

更新日期：2016-06-01 00:00:00

abstract：:Viral hemorrhagic fevers (VHFs) often cause high mortality with high infectivity, multiorgan failure, shock and hemorrhagic diathesis. Fibroblastic reticular cells (FRCs) within secondary lymphoid organs provide a supporting scaffold to T-lymphocyte areas. These cells regulate the movement of various immune cells and ...

journal_title：Immunotherapy

authors： Steele KE,Anderson AO,Mohamadzadeh M

更新日期：2009-03-01 00:00:00

abstract：:Over the last two decades, anti-CD20 monoclonal antibody (mAb) therapy has improved patient outcome in B-cell malignancies, and confirmed CD20 as an important target in chronic lymphocytic leukemia (CLL). Until recently, the gold standard was based on the utilization of rituximab combined with chemotherapy (fludarabin...

journal_title：Immunotherapy

authors： Bagacean C,Zdrenghea M,Tempescul A,Cristea V,Renaudineau Y

更新日期：2016-05-01 00:00:00

abstract：:Immunotherapy holds a highly promising treatment approach for metastatic melanoma patients. Adoptive cell transfer (ACT) involves the ex vivo expansion of autologous antitumor reactive lymphocytes and their reinfusion into lymphodepleted patients, accompanied by IL-2 administration. ACT with tumor-infiltrating T lymph...

journal_title：Immunotherapy

authors： Itzhaki O,Levy D,Zikich D,Treves AJ,Markel G,Schachter J,Besser MJ

更新日期：2013-01-01 00:00:00

abstract：:Sarcoidois is an inflammatory disease of unknown origin characterized by the abnormal accumulation of noncaseating granulomas at sites of disease activity in multiple organs throughout the body with a predilection for the lungs. Because the exact trigger that leads to disease activity is still under investigation, cur...

journal_title：Immunotherapy

authors： Celada LJ,Drake WP

更新日期：2015-01-01 00:00:00

abstract：:Aim: Assessment of safety, tolerability and changes in global clinical impression with an multiallergen immunotherapy treatment without dilutional effect in polyallergic patients. Patients & methods: This observational prospective study included patients with allergic rhinitis-rhinoconjunctivitis with or without asthm...

journal_title：Immunotherapy

authors： Alba P,Moreno V,Arias-Irigoyen J,Antón M,Parra A,Gómez-Fernández MC,Madariaga B,Martínez A,Begoña L

更新日期：2020-01-01 00:00:00

abstract：AIM:We developed a novel approach to efficiently deliver autologous tumor antigens to the cytoplasm of dendritic cells (DC) using yeast cell wall particles (YCWP). MATERIALS AND METHODS:Loading of YCWP, leakage of protein from loaded YCWP and cytoplasmic delivery of YCWP content was assessed using fluorescent-tagged e...

journal_title：Immunotherapy

authors： Hardin MO,Vreeland TJ,Clifton GT,Hale DF,Herbert GS,Greene JM,Jackson DO,Berry JE,Nichols P,Yin S,Yu X,Wagner TE,Peoples GE

更新日期：2018-04-01 00:00:00

abstract：:Targeted immunotherapies represent a valid strategy for the treatment of metastatic castrate-resistant prostate cancer. A randomized, double-blind, Phase II clinical trial of PROSTVAC® demonstrated a statistically significant improvement in overall survival and a large, global, Phase III trial with overall survival as...

journal_title：Immunotherapy

authors： Shore ND

更新日期：2014-01-01 00:00:00

abstract：:In recent years, there have been reports of immunotherapy inducing objective clinical responses in limited numbers of cancer patients. More frequently, however, clinical responses are not observed. Understanding the immunological mechanisms underlying successful immunotherapy are crucial if the field is to move forwar...

journal_title：Immunotherapy

authors： Hardwick N,Chain B

更新日期：2011-06-01 00:00:00

abstract：:In the last 10 years, cancer stem cells have interested the scientific community because this small tumorigenic population is also associated with tumor progression in human patients and specific targeting of cancer stem cells could be a strategy to eradicate cancers currently resistant to conventional therapy. Clinic...

journal_title：Immunotherapy

authors： Iovino F,Meraviglia S,Spina M,Orlando V,Saladino V,Dieli F,Stassi G,Todaro M

更新日期：2011-01-01 00:00:00

abstract：:Achieving long-term control of colorectal cancers with therapeutic vaccines that generate potent anti-tumor T cell and antibody responses has been a goal for more than two decades. To date, clinical trials of these vaccines have demonstrated induction of immune responses, but clinical benefit has been limited. Improve...

journal_title：Immunotherapy

authors： Patel SP,Osada T,Lyerly HK,Morse MA

更新日期：2014-01-01 00:00:00

abstract：AIM:Placenta specific 1 (PLAC1) is a protein rarely expressed in normal cells, except it is important for placental development, with a possible role in the establishment of the mother-fetus interface. The gene is also highly active in a wide variety of cancers and therefore, immunization with PLAC1 peptides could poss...

journal_title：Immunotherapy

authors： Liso A,Massenzio F,Stracci F

更新日期：2017-05-01 00:00:00

abstract：:Acute pyelonephritis is an infection of the renal parenchyma and renal pelvis. When it is caused by a typical pathogen in an immunocompetent female patient with normal urinary tract, it is considered uncomplicated. In all other cases, sepsis is the most worrisome complication. In the event of sepsis, patients should b...

journal_title：Immunotherapy

authors： Tsaganos T,Giamarellos-Bourboulis EJ

更新日期：2016-01-01 00:00:00

abstract：:Background: The purpose of this study was to assess the effectiveness of immune checkpoint inhibitors (ICIs) in advanced urothelial carcinoma. Materials & methods: We selected seven cohorts of patients published in four clinical trials. The restricted mean survival time (RMST) was used to analyze survival curves, perf...

journal_title：Immunotherapy

authors： Rivano M,Cancanelli L,Spazio LD,Chiumente M,Mengato D,Messori A

更新日期：2021-02-01 00:00:00

abstract：:Programmed cell death-1 protein (PD-1) is an immune checkpoint that has gained popularity in the treatment of several advanced cancers. Inhibiting this checkpoint is known to enhance immune response, but is also known to diminish immune tolerance and to increase autoimmune toxicity. We discuss a case of rapid onset fu...

journal_title：Immunotherapy

authors： Araújo M,Ligeiro D,Costa L,Marques F,Trindade H,Correia JM,Fonseca C

更新日期：2017-06-01 00:00:00

abstract：:Pediatric eosinophilic esophagitis is an inflammatory condition associated with marked eosinophil accumulation in the mucosal tissues of the esophagus. Eosinophils are major proinflammatory cells thought to make a major contribution to allergic diseases that affect the upper and lower airways, skin and GI tract. IL-5 ...

journal_title：Immunotherapy

authors： Walsh GM

更新日期：2010-07-01 00:00:00

abstract：:Glioblastoma multiforme (GBM), WHO grade IV astrocytoma, is the most dramatic primary brain cancer with a very poor prognosis due to inevitable disease recurrence. Less than 10% of GBM patients are still alive 5 years after diagnosis despite a multimodal treatment with surgical resection of the tumor, radiation therap...

journal_title：Immunotherapy

authors： Avril T,Vauleon E,Tanguy-Royer S,Mosser J,Quillien V

更新日期：2011-04-01 00:00:00

abstract：:Antibodies and antibody-based therapeutics have become big business, with annual sales over US$50 billion, accounting for >6% of worldwide pharmaceutical revenues. Ten molecules have blockbuster status (>US$1 billion), with six generating more than US$6 billion in sales. In excess of 300 products based on this rapidly...

journal_title：Immunotherapy

authors： Larrick JW

更新日期：2012-03-01 00:00:00

abstract：AIM:There is still no specific therapy for infection with the highly pathogenic avian influenza A virus (HPAI) H5N1, which caused 39 human cases with a 64% fatality rate in 2013. MATERIALS & METHODS:We prepared highly purified specific equine polyclonal immunoglobulin fragments (F(ab')2) against H5N1 and tested them f...

journal_title：Immunotherapy

authors： Herbreteau CH,Jacquot F,Rith S,Vacher L,Nguyen L,Carbonnelle C,Lotteau V,Jolivet M,Raoul H,Buchy P,Saluzzo JF

更新日期：2014-01-01 00:00:00

abstract：:The rapid emergence of multidrug-resistant pathogens, especially Gram-negative bacteria and mycobacteria, represents one of the major medical challenges of the 21st century. The gradual loss of effective classical antibiotics for many bacterial pathogens, combined with an increasing population density and mobility, ur...

journal_title：Immunotherapy

authors： Helbig ET,Opitz B,Sander LE

更新日期：2013-04-01 00:00:00

abstract：:Evaluation of: Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6(224), 224ra25 (2014). Recently, chimeric antigen receptor (CAR) T-cell immunotherapy has entered clinical trials in patients with relapsed or refr...

journal_title：Immunotherapy

authors： Patel JM,Dale GA,Vartabedian VF,Dey P,Selvaraj P

更新日期：2014-01-01 00:00:00

abstract：:Epstein-Barr virus (EBV) infection is associated with a range of human malignancies of lymphocytic and epithelial cell origin. In addition to viral-mediated and genetic oncogenic events that lead to the establishment of EBV-associated malignancies, defects in the immune control of EBV likely play a significant role in...

journal_title：Immunotherapy

authors： Smith C,Khanna R

更新日期：2015-01-01 00:00:00

abstract：:In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the disease. Itolizumab is a monoclonal antibody that recognizes human CD6 expressed in activated T cells. The antibody has shown to be safe and efficacious in the treatment of moderate to severe psoriasis. Its effect is asso...

journal_title：Immunotherapy

authors： Filgueira LM,Cervantes JB,Lovelle OA,Herrera C,Figueredo C,Caballero JA,Sánchez N,Berrio J,Lorenzo G,Cepeda M,Ramos M,Saavedra D,Añe-Kouri AL,Mazorra Z,Leon K,Crombet T,Caballero A

更新日期：2021-03-01 00:00:00

abstract：:Aim: Previously, we constructed a novel anti-p21Ras single-chain antibody fragment, KGH-R1-single-chain fragment variant (ScFv). However, the immunoreactivity of this antibody toward p21Ras is still unclear. Materials & methods: ELISAs, immunohistochemistry, western blotting and immunofluorescence were used to identif...

journal_title：Immunotherapy

authors： Wang P,Pan X,Feng Q,Zou H,Cui J,He Y,Luo Y,Yang J

更新日期：2020-08-01 00:00:00

abstract：:Aim: To analyze the efficacy of checkpoint inhibitors in soft tissue sarcoma. Materials & methods: We retrospectively reviewed patients with advanced soft tissue sarcoma treated with ipilimumab and nivolumab. All patients who received at least one cycle were included. Results: One patient had a complete response and f...

journal_title：Immunotherapy

authors： Zhou M,Bui N,Bolleddu S,Lohman M,Becker HC,Ganjoo K

更新日期：2020-12-01 00:00:00

abstract：:Cancer-testis (CT) antigens are tumor-associated antigens attracting immunologists for their possible application in the immunotherapy of cancer. Several clinical trials have assessed their therapeutic potentials in cancer patients. Breast cancers, especially triple-negative cancers are among those with significant ex...

journal_title：Immunotherapy

authors： Ghafouri-Fard S,Shamsi R,Seifi-Alan M,Javaheri M,Tabarestani S

更新日期：2014-01-01 00:00:00

abstract：:While the etiology of multiple sclerosis (MS) remains unclear, research from the clinic and preclinical models identified the essential role of inflammation and demyelination in the pathogenesis of MS. Current treatments focused on anti-inflammatory processes are effective against acute episodes and relapsing-remittin...

journal_title：Immunotherapy

authors： Robinson RR,Dietz AK,Maroof AM,Asmis R,Forsthuber TG

更新日期：2019-02-01 00:00:00

abstract：:Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients & methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/O...

journal_title：Immunotherapy

authors： Moreau P,Hebraud B,Facon T,Leleu X,Hulin C,Hashim M,Hu Y,Caillot D,Benboubker L,Zweegman S,Merz M,Weisel K,Salwender H,Mai EK,Goldschmidt H,Bertsch U,Vanquickelberghe V,Kampfenkel T,Boer C,Krotneva S,Proskorovsky

更新日期：2021-02-01 00:00:00

abstract：:Activation of a patient's immune system offers an attractive approach to prevent and treat hepatocellular carcinoma (HCC). However, the antitumor efficacy of current HCC vaccines was weak owing to insufficient immune activation of targeting self/tumor antigens. We recently found that epitope-optimized α-fetoprotein ef...

journal_title：Immunotherapy

authors： He Y,Hong Y,Mizejewski GJ

更新日期：2014-01-01 00:00:00

abstract：:Evaluation of: Boudousq V, Ricaud S, Garambois V et al.: Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing (125)I-labeled monoclonal antibodies. J. Nucl. Med. 51, 1748-1755 (2010). Mesothelioma, pseudomyxoma peritonei, ovarian and colon cancers, and s...

journal_title：Immunotherapy

authors： Baranowska-Kortylewicz J

更新日期：2011-04-01 00:00:00